Cantor starts Tocagen with Overweight rating, $28 price target. Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Tocagen with an Overweight rating and $28 price target. Tocagen focuses on cancer-specific gene therapy drugs utilizing a retroviral replicating vector platform, Piros tells investors in a research note. The analyst believes Toca 511 and Toca FC could become an effective treatment option in recurrent high grade glioma, “where there is a significant unmet need with low survival rates.”
https://thefly.com/landingPageNews.php?id=2898333
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.